Patents Issued in September 24, 2024
  • Patent number: 12097244
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: September 24, 2024
    Assignee: Altor BioScience, LLC.
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Patent number: 12097245
    Abstract: A pharmaceutical composition having a hypoglycemic effect, comprising: a GLP-1 receptor agonist, and a composition for promoting small-intestinal absorption; wherein the composition for promoting small-intestinal absorption comprises sodium lauryl sulfate, carbomer, chitosan, and sodium citrate. The composition for promoting small intestinal absorption according to the present invention may be prepared into a composite adjuvant, which, when combined with a GLP-1 agonist, can improve the absorption of this active ingredient in the small intestine and the like.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: September 24, 2024
    Inventor: Jing Zhang
  • Patent number: 12097246
    Abstract: The invention is directed to a method of treating a spinal cord injury, a neurodegenerative disease or a neuronal injury in an individual in need thereof comprising administering an effective amount of superoxide dismutase (SOD) and catalase to the individual, wherein the superoxide dismutase and the catalase are encapsulated in one or more nanoparticles that release the SOD and catalase upon administration. Another aspect of the invention is directed to compositions comprising superoxide dismutase (SOD) and catalase encapsulated in one or more nanoparticles.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: September 24, 2024
    Assignee: The Cleveland Clinic Foundation
    Inventors: Vinod Labhasetwar, Hayder H. Jaffer
  • Patent number: 12097247
    Abstract: The present invention relates to a pharmaceutical composition for treating gout and a gout treatment kit. According to an embodiment of the present invention, a pharmaceutical composition for treating gout comprising a probe containing at least one or more peptides specifically coupled to a monosodium urate (MSU) crystals and a first enzyme which is coupled to the probe and reacts with the target MSU crystal coupled to the probe or urea of surrounding joint fluid to remove the target MSU crystal is provided.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: September 24, 2024
    Assignee: UNIVERSITY-INDUSTRY FOUNDATION(UIF), YONSEI UNIVERSITY
    Inventor: Jae-Chul Pyun
  • Patent number: 12097248
    Abstract: A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: September 24, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Patent number: 12097249
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: September 24, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Patent number: 12097250
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: September 24, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
  • Patent number: 12097251
    Abstract: Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 24, 2024
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Daning Wang, Jie Chen, Ying Gu, Jun Zhang, Ningshao Xia
  • Patent number: 12097252
    Abstract: The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: September 24, 2024
    Assignee: 1SA PHARMACEUTICALS B.V.
    Inventor: Gwenn Eveline Mulder
  • Patent number: 12097253
    Abstract: The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with Respiratory syncytial virus (RSV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.
    Type: Grant
    Filed: February 28, 2024
    Date of Patent: September 24, 2024
    Assignee: CureVac SE
    Inventors: Johannes Lutz, Susanne Rauch, Regina Heidenreich, Benjamin Petsch
  • Patent number: 12097254
    Abstract: The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a host. The rabies composition is more stable and safe, and is able to induce earlier and higher titers of neutralizing antibody.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: September 24, 2024
    Assignee: Yisheng Biopharma (Singapore) PTE LTD
    Inventors: Lietao Li, Yi Zhang, Fang Liu
  • Patent number: 12097255
    Abstract: The present invention provides: a recombinant expression vector comprising a gene encoding a porcine parvovirus VP2 protein; a recombinant plant or a recombinant insect cell transformed with the vector; and a vaccine composition for a porcine parvovirus and a composition for diagnosing porcine parvovirus, both of which contain a porcine parvovirus VP2 protein obtained from the recombinant plant or the recombinant insect cell. When the recombinant plant or recombinant insect cell of the present invention is used, the porcine parvovirus antigenic protein can be produced with high efficiency, and the porcine parvovirus antigenic protein production method using the recombinant plant or recombinant insect cell has excellent safety and stability compared with other antigen production methods.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 24, 2024
    Assignees: REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY), BIOAPPLICATIONS INC.
    Inventors: Jae-Young Song, In-Ohk Ouh, Soodong Cho, Yongjik Lee, Ju-Yeon Lee, In-Soo Cho
  • Patent number: 12097256
    Abstract: Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound demonstrating enhanced stability, which in some embodiments comprises a protein and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for unrefrigerated storage for longer time periods than previous approaches, thus making feasible access to such products over a global supply chain.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: September 24, 2024
    Assignee: KBIO HOLDINGS LIMITED
    Inventors: Leigh Burden, Steven D. Hume, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, John W. Shepherd
  • Patent number: 12097257
    Abstract: Provided are polynucleotides and viral vectors, particularly, Alphavirus vectors such as Sindbis viral vectors, which encode an immune checkpoint protein, or a ligand binding portion of the checkpoint protein, or an immune checkpoint protein or ligand binding portion thereof fused to one or more immunoglobulin (Ig) domains, e.g., an Ig hinge region and an Ig heavy chain constant domain. Methods of treating a mammalian subject having a cancer or tumor are provided, in which the viral vectors, e.g., a Sindbis virus vector, encoding the immune checkpoint protein, a ligand binding portion thereof, or a checkpoint protein fusion protein as described, are administered to the subject, resulting in an anti-cancer or anti-tumor immune response, significant reduction in tumor growth in the treated subject and increased survivability.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: September 24, 2024
    Assignee: New York University
    Inventors: Daniel Meruelo, Alicia Hurtado Martinez, Christine Pampeno, Iris Scherwitzl
  • Patent number: 12097258
    Abstract: A Dectin-2 ligand vaccine adjuvant and a method of making and using the Dectin-2 ligand vaccine adjuvant in a vaccine to immunize a patient are disclosed. Also discloses is a vaccine composition comprising a Bl-Eng2 antigen and methods of using the vaccine composition to immunize a subject against a fungal infection.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: September 24, 2024
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Bruce Steven Klein, Huafeng Wang, Marcel Wuethrich, Tristan Theodore Brandhorst
  • Patent number: 12097259
    Abstract: The present disclosure provides a dendric cell tumor vaccine comprising a chimeric antigen receptor for activating the dendritic cell and a tumor antigen. The present disclosure also provides compositions and methods of making the dendritic cell tumor vaccine, and the methods of using the dendritic cell tumor vaccine to treat cancer.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: September 24, 2024
    Assignee: SHENZHEN FRONTIERGATE BIOTECHNOLOGY CO., LTD
    Inventor: Yang Xu
  • Patent number: 12097260
    Abstract: A polymer composition can include an aqueous vehicle and a temperature-responsive degradable polymer having a polymer including a LCST-imparting unit and a lactone-bearing unit including a pendent lactone group. The number of LCST-imparting units is greater than the number of lactone-bearing units. The temperature-responsive degradable polymer has an initial lower critical solution temperature (LCST) of 37° C. or below. The polymer composition can have a pH lower than 7.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: September 24, 2024
    Assignee: Sonoran Biosciences, Inc.
    Inventor: Derek J. Overstreet
  • Patent number: 12097261
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 24, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
  • Patent number: 12097262
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: September 24, 2024
    Assignee: The Regents of the University of California
    Inventors: Kevan Shokat, Masanori Okaniwa
  • Patent number: 12097263
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Grant
    Filed: January 19, 2024
    Date of Patent: September 24, 2024
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins
  • Patent number: 12097264
    Abstract: Provided herein is a nanoparticle for drug delivery, wherein the nanoparticle comprises a hyperbranched polyester (HBPE) nanoparticle having a hydrophobic interior, polyglutamate folate ligands conjugated to the nanoparticle, and one or more PET detectable isotopes. Also provided herein are methods of using thereof.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: September 24, 2024
    Assignees: University of Central Florida Research Foundation, Inc., et al., Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, , Memorial Sloan Kettering Cancer Center
    Inventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
  • Patent number: 12097265
    Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 receptors on a cancer cell.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: September 24, 2024
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Xiaojuan Gong, Minoo J Moghaddam, Julian Alexander Barden
  • Patent number: 12097266
    Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: September 24, 2024
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: B. Rabindran Jermy, Vijaya Ravinayagam, Dana Almohazey
  • Patent number: 12097267
    Abstract: Codon optimized nucleic acid sequences for the long form and short form of RdCVF are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequences. Recombinant vectors are provided that express the codon optimized RdCVFL and RdCVF individually, or express two copies of a codon optimized RdCVF or RdCVFL nucleic acid sequence, or both RdCVFL and RdCVF in a single vector or virus. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence or inappropriate expression of RdCVF and RdCVFL.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: September 24, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jeannette Bennicelli, Jean Bennett, Junwei Sun
  • Patent number: 12097268
    Abstract: Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: September 24, 2024
    Assignee: EOS Neuroscience, Inc.
    Inventors: Alan Horsager, Andrew Smith, Benjamin C. Matteo
  • Patent number: 12097269
    Abstract: Provided herein are nanoparticle-based gadolinium (Gd) agents which may be used, e.g., in T1-weighted MR imaging (MRI). In various embodiments, dual-Gd liposomal agents are provided which contain both core-encapsulated Gd as well as surface-conjugated Gd. In various embodiments, these agents were observed to deliver a higher concentrations of Gd and result in substantial improvements in signal to noise ratios and contrast to noise ratios. Also provided are methods for in vivo imaging and/or treating diseases such as cancer or tumor in a subject.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 24, 2024
    Inventors: Vikas Kundra, James A. Bankson, Ananth Annapragada, Ketan B. Ghaghada, Murali K. Ravoori
  • Patent number: 12097270
    Abstract: Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: September 24, 2024
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Carol Walker, David C. Onthank, Joel Lazewatsky, Nhung Tuyet Nguyen
  • Patent number: 12097271
    Abstract: Dental root canal filling composition comprising (a) one or more diepoxides; (b) one or more primary monoamines and/or disecondary diamines; (c) a particulate filler, wherein the one or more diepoxides are selected from compounds of the following formula (I) or a salt thereof:
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: September 24, 2024
    Assignee: DENTSPLY SIRONA INC.
    Inventors: Joachim E. Klee, Matthias Worm
  • Patent number: 12097272
    Abstract: An ultraviolet protection patch is provided. An ultraviolet protection patch, according to one embodiment of the present invention, is implemented by comprising: an ultraviolet protection layer including a support component and an ultraviolet protection agent; and a first shape-retaining layer which is a fiber web provided on one surface of the ultraviolet protection layer.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: September 24, 2024
    Assignee: AMOLIFESCIENCE CO., LTD.
    Inventors: Su Yeon Lee, Ji Young Kim, Hyo Jung Lee, In Yong Seo, Seoung Hoon Lee
  • Patent number: 12097273
    Abstract: Disclosed is a method of treating skin with a composition comprising an extract from Magnolia officinalis.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: September 24, 2024
    Assignee: MARY KAY INC.
    Inventors: Jim Faller, David Gan, Michelle Hines, Lisa Mangos
  • Patent number: 12097274
    Abstract: The subject of the present application is an agent for the oxidative dyeing of keratinous fibers, in particular human hair, which contains the coupling oxidation dye precursor 2-(1,3-benzodioxol-5-ylamino)ethanol in combination with the oxidation base 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: September 24, 2024
    Assignee: Henkel AG & Co. KGaA
    Inventors: Razi Abbas, Tugce Cansev, Thomas Hippe, Astrid Kleen, Hartmut Manneck, Stefan Hoepfner, Tiffany Lea Fielder
  • Patent number: 12097275
    Abstract: A hair coloring method may include a step of applying a mixture of the following (A) and (B) in a predetermined ratio: (A) a hair coloring agent comprising at least a basic dye, a HC dye, a second amino acid, a first cationic surfactant, a thickener, an oil agent, a first pH adjusting agent, a wetting agent and at least one selected from the group consisting of thioglycolic acid, cysteine, 3-mercapto-1,2-propanediol, cysteamine, and derivatives and salts thereof, wherein the pH of the hair coloring agent is pH 3.5 or higher, and (B) a hair cosmetics comprising at least an alkaline agent, a first amino acid, higher alcohols having 12 to 22 carbon atoms, a surfactant, and a thickener. The hair coloring method may further include a step of providing a predetermined time after the application.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: September 24, 2024
    Assignee: SUNNYPLACE CO., LTD.
    Inventors: Nobuhito Mukai, Takashi Mukai
  • Patent number: 12097276
    Abstract: A composition contains, as an effective component, theasinensin A, an enantiomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The composition has an excellent stability and provides wrinkle-reducing or skin elasticity-enhancing benefits, and skin-brightening benefits by containing theasinensin A, an enantiomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, as an effective component.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: September 24, 2024
    Assignees: AMOREPACIFIC CORPORATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Eun Mi Kim, Kyeonghwan Hwang, Dong Hyun Kim, Byung-Gee Kim, Jinkyung Choi
  • Patent number: 12097277
    Abstract: A sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 ?mol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 ?mol per gram polymer, wherein the composition has a residual thiol content of less than 20% in respect to the degree of modification of the thiol-modified hyaluronan.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 24, 2024
    Assignee: CROMA-PHARMA GMBH
    Inventors: Martin Prinz, Ralph Hollaus, Robert Sachsenhofer
  • Patent number: 12097278
    Abstract: Film forming compositions and methods for preventing stains and increasing shine and gloss of teeth. The film forming compositions may include a polymer, such as a hydrophobic polymer, and an orally acceptable solvent. The hydrophobic polymer may include an acrylate component and a hydrophobic group coupled with one another. The hydrophobic group may include an alkyl chain, a polyethylene glycol, a polypropylene, a polyester, a polyorthoester, a phospholipid, a long chain fatty acid, a vinyl chloride, fluorethylene, a siloxane, a urethane, an octylacrylamide, a butylaminoethyl, a styrene, and combinations thereof.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: September 24, 2024
    Assignee: Colgate-Palmolive Company
    Inventors: Michael North, Rong Dong, Paloma Pimenta, Shira Pilch
  • Patent number: 12097279
    Abstract: A particular composition of the present disclosure is designed to work as a topical composition. The composition relies on a unique combination of any one of, any combination of, or all of Brassica campestris (rapeseed) sterols, Rhododendron ferrugineum extract, Oenothera biennis (evening primrose) oil, and a combination of peptides and polypeptides. The compositions are useful for moisturizing and conditioning the skin.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: September 24, 2024
    Assignee: MARY KAY INC.
    Inventors: Patricia Jacoby, David Gan, Geetha Kalahasti
  • Patent number: 12097280
    Abstract: Personal care compositions and methods for treating one or more dry skin conditions are disclosed. The composition may include a carrier, one or more plant oils, and a source of Aloe vera. The one or more plant oils and the source of Aloe vera may each be present in an effective amount to increase natural moisturizing factors in skin when applied thereto. The method for treating the one or more dry skin conditions may include contacting the personal care composition with skin. Contacting the personal care composition with the skin may increase an amount of natural moisturizing factors in the skin and/or increase an amount of Caspase-14 in the skin.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: September 24, 2024
    Assignee: Colgate-Palmolive Company
    Inventors: Qiang Wu, Laurence Du-Thumm, Shujiang Cheng, Adriana Armas, Luis Miguel Lopez, Alejandro Meneses
  • Patent number: 12097281
    Abstract: A composition for improving skin moisturization of companion animals, including 10 to 20 parts by weight (“wt. parts”) of olive oil, 5 to 10 wt. parts of oleanolic acid acetate powder, 30 to 40 wt. parts of barley sprout fermented extract powder, 30 to 40 wt. parts of broccoli sprout fermented extract powder, 5 to 15 wt. parts of coconut extract fine powder, 1.5 to 2.5 wt. parts of sodium hyaluronate purified powder, 5.5 to 10 wt. parts of trehalose powder, 5 to 10 wt. parts of chlorella powder, and 5 to 10 wt. parts of green leaf mussel extract powder, based on 100 wt. parts of purified water.
    Type: Grant
    Filed: April 9, 2024
    Date of Patent: September 24, 2024
    Inventor: Tae Yoon Kim
  • Patent number: 12097282
    Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: September 24, 2024
    Assignee: The General Hospital Corporation
    Inventors: Lilit Garibyan, William A. Farinelli, Richard Rox Anderson, Emilia Javorsky
  • Patent number: 12097283
    Abstract: Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240° C. to 280° C.
    Type: Grant
    Filed: September 19, 2022
    Date of Patent: September 24, 2024
    Assignees: Chang Gung University, Giant Bio Technology Inc.
    Inventors: Jui-Yang Lai, Chih-Ching Huang, Han-Jia Lin, Hong-Jyuan Jian
  • Patent number: 12097284
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: September 24, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 12097285
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: September 24, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 12097286
    Abstract: A confectionery method includes dissolving at least one active ingredient in a volatile vehicle to form a solution, applying the solution to a substrate and evaporating the volatile vehicle to leave the at least one active ingredient applied to the substrate. A confection includes an edible substrate and at least one active ingredient provided to the edible substrate.
    Type: Grant
    Filed: January 4, 2024
    Date of Patent: September 24, 2024
    Inventors: Erik Lawrence Kreider, Bryan E. Burke
  • Patent number: 12097287
    Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: September 24, 2024
    Assignee: BELHAVEN BIOPHARMA INC.
    Inventors: Scott Lyman, Barry Bleske, Ted William Lanpher
  • Patent number: 12097288
    Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: September 24, 2024
    Assignee: Cristcot LLC
    Inventor: Jennifer J. Davagian
  • Patent number: 12097289
    Abstract: The disclosure provides stable formulations of cationic biocides that are primarily used in the treatment and prevention of infections. The disclosure is also concerned with processes for forming stable emulsions of cationic biocides and petrolatum.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: September 24, 2024
    Assignee: GLOBAL HEALTH SOLUTIONS LLC
    Inventor: Bradley Burnam
  • Patent number: 12097290
    Abstract: Provided are nanoparticles and methods of using and making thereof. The inventive nanoparticle comprises a) an inner core comprising a non-cellular material; and b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus. Medicament delivery systems or pharmaceutical compositions comprising the inventive nanoparticles are also provided. Further provided are immunogenic compositions comprising the inventive nanoparticles, and methods of using the inventive immunogenic compositions for eliciting an immune response, and for treating or preventing diseases or condition, such as neoplasm or cancer, or disease or conditions associated with cell membrane inserting toxin. Vaccines comprising the immunogenic composition comprising the nanoparticles are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 24, 2024
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Che-Ming (Jack) Hu, Ronnie Hongbo Fang, Jonathan Copp
  • Patent number: 12097291
    Abstract: Compositions relating to thermostable vaccines and methods of preparing the same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: September 24, 2024
    Assignees: The Regents of the University of Colorado, a body corporate, Soligenix, Inc.
    Inventors: Kimberly Hassett, Pradyot Nandi, Robert N. Brey, John Carpenter, Theodore Randolph
  • Patent number: 12097292
    Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: September 24, 2024
    Assignee: MAPI PHARMA LTD.
    Inventors: Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
  • Patent number: 12097293
    Abstract: Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: September 24, 2024
    Assignee: Pike Therapeutics Inc.
    Inventors: Fotios M. Plakogiannis, Tamanna Lather, Nisarg Modi, Marina Borovinskaya